Familial Periodic Paralyses |
|
|
Clinical Trial: Study of Novel Types of Familial Diabetes Insipidus
This study has been suspended.
|
Purpose
OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
| Condition | Treatment or Intervention |
|---|---|
| Diabetes Insipidus | Drug: desmopressin |
MedlinePlus related topics: Diabetes Insipidus
Study Type: Observational
Study Design: Screening
Expected Total Enrollment: 5
Study start: December 1995
PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed. Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype. Participants determined to have DI are treated with desmopressin for 2 days.
Eligibility
Ages Eligible for Study: 6 Months - 70 Years, Genders Eligible for Study: Both
Criteria
- Familial diabetes insipidus (DI) in atypical or novel form, e.g.: Dipsogenic DI Neurohypophyseal DI
- Affected and unaffected members of kindreds eligible
Location Information
Gary L. Robertson, Study Chair, Northwestern University
More Information
Record last reviewed: October 2003
Last Updated: October 13, 2004
Record first received: October 18, 1999
ClinicalTrials.gov Identifier: NCT00004364
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


